[go: up one dir, main page]

NO933918L - 2- og 5-alkyl-og fenylsubstituerte 4- (1-hydroksy-, 1-acyloksy- e ller 1- karbamoyloksy)-5-hydroksy-2(5H)- furanoner som anti-inflammatorisk e midler - Google Patents

2- og 5-alkyl-og fenylsubstituerte 4- (1-hydroksy-, 1-acyloksy- e ller 1- karbamoyloksy)-5-hydroksy-2(5H)- furanoner som anti-inflammatorisk e midler

Info

Publication number
NO933918L
NO933918L NO933918A NO933918A NO933918L NO 933918 L NO933918 L NO 933918L NO 933918 A NO933918 A NO 933918A NO 933918 A NO933918 A NO 933918A NO 933918 L NO933918 L NO 933918L
Authority
NO
Norway
Prior art keywords
alkyl
phenyl
hydroxy
substituted phenyl
carbons
Prior art date
Application number
NO933918A
Other languages
English (en)
Other versions
NO933918D0 (no
Inventor
Gary C M Lee
Michael E Garst
George Sachs
Inc Allergan
Original Assignee
Lee Gary C. M.
Garst Michael E.
George Sachs
Inc Allergan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Gary C. M., Garst Michael E., George Sachs, Inc Allergan filed Critical Lee Gary C. M.
Publication of NO933918D0 publication Critical patent/NO933918D0/no
Publication of NO933918L publication Critical patent/NO933918L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Nye anti-inflammatoriske furanonforbindelser har følgende formel hvor R1 uavhengig er H, fenyl, C^-Ctalkylsubstituert fenyl, halogensubstituert fenyl, eller alkyl med l til 6 karbon- atomer, og n er et helt tall med verdier på l eller 2, og hvor når n er l, er Ri-gruppen bundet enten til 3- eller 5-still- ingen i 2-furanonet, når n er 2, er Rj. bundet til både 3- og 5- stillingen, under den forutsetning at når n er l, er R! ikke H; Y! er H, alkyl med l til 20 karbonatomer, fenyl-Ci-C^alkyl, C±- C20alkenyl inneholdende en eller flere olefinbindinger, PO(OH)2, PO(OH)OR2, PO(OH)R2, PO(OR2)2, hvor R2 uavhengig er alkyl med l til 20 karbonatomer, fenyl, eller halogensubsti- tuert fenyl eller Ci-Cjalkylsubstituert fenyl, YL videre er CO- R3, CO-OR3, CONHR3, S02R3, S02NHR3, (CH2)p-O-R3, eller (CH2)p-O- (CH2)m-0-R3, hvor p og m er hele tall og uavhengig er l til 20, og R3 er H, Cj_-C20alkyl, Ci-Czoalkenyl inneholdende en eller flere olefinbindinger, fenyl, halogensubstituert fenyl eller Ci-C6alkylsubstituert fenyl, under den forutsetning at når Y! er CO-R3, CO-ORj og CONHR3, er R3 ikke hydrogen; Y2 er H, en alkylgruppe med l til 25 karbonatomer, fenyl, naftyl, fenyl(CL C20)alkyl-, naftyl (C^-CZQ) alkyl-, halogensubstituert fenyl, G!~ C6akyl-substituert fenyl, halogensubstituert naftyl, C^-CjSub- stituert naftyl; Y3 er H, alkyl med l til 20 karbonatomer, CO- Rt, CO-0-R4, CO-NH-RA, PO(ORJZ eller PO(ORJR4, hvor R4 uavhen- gig er H, alkyl med l til 20 karbonatomer, fenyl eller halo- gensubstituert fenyl eller Ci-Cealkylsubstituert fenyl.
NO933918A 1991-04-30 1993-10-29 2- og 5-alkyl-og fenylsubstituerte 4- (1-hydroksy-, 1-acyloksy- e ller 1- karbamoyloksy)-5-hydroksy-2(5H)- furanoner som anti-inflammatorisk e midler NO933918L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/693,204 US5183906A (en) 1991-04-30 1991-04-30 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
PCT/US1992/003623 WO1992019610A1 (en) 1991-04-30 1992-04-29 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2(5h)-furanones as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
NO933918D0 NO933918D0 (no) 1993-10-29
NO933918L true NO933918L (no) 1993-12-28

Family

ID=24783742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933918A NO933918L (no) 1991-04-30 1993-10-29 2- og 5-alkyl-og fenylsubstituerte 4- (1-hydroksy-, 1-acyloksy- e ller 1- karbamoyloksy)-5-hydroksy-2(5H)- furanoner som anti-inflammatorisk e midler

Country Status (10)

Country Link
US (1) US5183906A (no)
EP (1) EP0579769B1 (no)
JP (1) JP3181054B2 (no)
AT (1) ATE172459T1 (no)
AU (1) AU1923892A (no)
CA (1) CA2109064A1 (no)
DE (1) DE69227366T2 (no)
ES (1) ES2124261T3 (no)
NO (1) NO933918L (no)
WO (1) WO1992019610A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
WO1994026279A1 (en) * 1993-05-18 1994-11-24 The Upjohn Company Bisphosphonate esters for treating gastric disorders
KR960703901A (ko) * 1993-08-19 1996-08-31 로즈 암스트롱 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)
US5464865A (en) * 1993-12-22 1995-11-07 Ortho Pharmaceutical Corporation 4-aryl- and 4-arylthio-5-hydroxy-2(5H)-furanones as inhibitors of phospholipase A2
US5451686A (en) * 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
US5922759A (en) * 1996-06-21 1999-07-13 Warner-Lambert Company Butenolide endothelin antagonists
AU6603996A (en) * 1995-08-24 1997-03-19 Warner-Lambert Company Furanone endothelin antagonists
US5891892A (en) * 1996-10-29 1999-04-06 Warner-Lambert Company Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
FR2978963A1 (fr) 2011-08-11 2013-02-15 Ascorbix Nouveaux derives des furanones et composition pharmaceutique les contenant

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
EP0133376B1 (en) * 1983-08-03 1988-07-27 The Regents Of The University Of California Synthetic analgesic and/or anti-inflammatory derivatives of manoalide
US4447445A (en) * 1983-08-03 1984-05-08 The Regents Of The University Of Calif. Manoalide, an anti-inflammatory analgesic marine natural product
US4789749A (en) * 1984-06-18 1988-12-06 The Regents Of The University Of California Manoalide analogs
US4874782A (en) * 1985-07-01 1989-10-17 Eli Lilly And Company Furanone derivatives
ZA864674B (en) * 1985-07-01 1988-02-24 Lilly Co Eli Furanone derivatives
US4786651A (en) * 1986-02-03 1988-11-22 Allergan, Inc. Treatment of cutaneous hyperproliferative dermatoses with manoalide
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
US5043457A (en) * 1990-04-17 1991-08-27 Allergan, Inc. 2(5H)-furanones substituted in the 3 position, as Ca2+ channel antagonists and anti-inflammatory agents
CA1329390C (en) * 1987-06-08 1994-05-10 John N. Bonfiglio Anti-inflammatory furanones
US5059611A (en) * 1988-11-18 1991-10-22 Allergan, Inc. Anti-inflammatory 5-hydroxy-2-furanones
US5089485A (en) * 1988-11-18 1992-02-18 Allergan, Inc. Anti-inflammatory furanones
US5037811A (en) * 1990-04-17 1991-08-06 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US4916241A (en) * 1988-06-06 1990-04-10 American Home Products Corporation Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
JPH0222271A (ja) * 1988-07-11 1990-01-25 Kuraray Co Ltd 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
US4935530A (en) * 1988-10-18 1990-06-19 Allergan, Inc. Process for preparing 5-substituted-3-furaldehydes
EP0369813A3 (en) * 1988-11-18 1991-02-27 Allergan, Inc Anti-inflammatory furanones
EP0372941A3 (en) * 1988-12-07 1991-02-06 Allergan, Inc Anti-inflammatory 5-hydroxy-2-furanones
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
US5013850A (en) * 1990-03-30 1991-05-07 Allergan, Inc. 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents

Also Published As

Publication number Publication date
JPH06507171A (ja) 1994-08-11
WO1992019610A1 (en) 1992-11-12
JP3181054B2 (ja) 2001-07-03
ATE172459T1 (de) 1998-11-15
US5183906A (en) 1993-02-02
EP0579769A1 (en) 1994-01-26
DE69227366T2 (de) 1999-06-10
CA2109064A1 (en) 1992-10-31
DE69227366D1 (de) 1998-11-26
ES2124261T3 (es) 1999-02-01
NO933918D0 (no) 1993-10-29
AU1923892A (en) 1992-12-21
EP0579769B1 (en) 1998-10-21

Similar Documents

Publication Publication Date Title
NO933918L (no) 2- og 5-alkyl-og fenylsubstituerte 4- (1-hydroksy-, 1-acyloksy- e ller 1- karbamoyloksy)-5-hydroksy-2(5H)- furanoner som anti-inflammatorisk e midler
AU653057B2 (en) Cosmetic composition
AU585452B2 (en) Oxiranes
BR8707408A (pt) Novos 5-alcoxi-2,4-diamino-alquibenzenos e composicoes de tingimento de cabelo com 5-alcoxi-2,4-diamino-alquil-benzenos
ES527954A1 (es) Un procedimiento para preparar isoxazoles
DE69725708D1 (de) Neue poly(monoperoxycarbanate)
ATE18768T1 (de) Neue 6-alpha-methylprednisolon-derivate ihre herstellung und verwendung.
ATE165972T1 (de) 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel
AU539290B2 (en) Stabilized peroxygenated compounds
AU533417B2 (en) Mixtures of stilbene optical brighteners
DK0460488T3 (da) Svovlholdige heterocykliske forbindelser
FI892681A0 (fi) Nya jodade icke-joniska trijodbenzenfoereningar och dessa innehaollande kontrastmedel.
AU552310B2 (en) 4-aroylimidazolin-2-ones
NZ232687A (en) 1(substituted alkyl)oxy-2-(methoxymethylidinyl or methoxyimino)carboxy methyl naphthalene methyl ester derivatives
AU550155B2 (en) 3-oxabicyclo(3.1.0)hexan-2-ones
FI960929L (fi) Välituotteena käyttökelpoiset indolonijohdannaiset
FI865121A0 (fi) Foerfarande foer genomfoerande av magnetiska kretsar foer stabiliseringsspolar till anvaendning i en kombination av lampor med olika urladdning.
JPS56142228A (en) Manufacture of chlorophenols
GB2018251A (en) Cyclic acetals
ATE99306T1 (de) Antagonisten von leukotrien d4.